IBRX — ImmunityBio, Inc.

Is IBRX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

ImmunityBio, Inc. (IBRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $5.98. The rating moved from Strong Oversold to Oversold on November 13, 2026.

See all oversold Healthcare stocks →

AI analysis

ImmunityBio, Inc. (IBRX) is positioned as a clinical-stage biotech where value is driven primarily by binary clinical and partnership milestones rather than commercial cash flows. The company's near-term outlook hinges on trial outcomes and financing flexibility; limited revenue and sector-wide convertible/debt trends raise dilution and volatility risks. Sector flows favoring large-cap pharma may constrain retail and institutional demand for smaller, higher-risk biotech names. Upside could materialize from positive clinical readouts or strategic collaborations, while downside is concentrated in failed trials, cash shortfalls, or unfavorable financing conditions. Given these factors, a neutral stance is warranted with close monitoring of cash runway, upcoming catalysts, and any financing activity.

Key factors

  • Clinical-stage therapeutic pipeline with binary, near-term catalysts tied to trial readouts or partner deals
  • Limited or no recurring commercial revenue; financial position likely dependent on external financing or milestone receipts
  • Historical convertible-debt / financing dynamics in the sector increase potential for dilution and hedging-driven stock pressure
  • Sector investor flows favor large-cap pharma and defensive names, which can reduce appetite for small-cap biotech exposure
  • Potential upside from positive clinical data, licensing/partnership agreements, or meaningful non-dilutive financing

Risks

  • Negative or inconclusive clinical trial results or regulatory setbacks that materially reduce valuation
  • Insufficient cash runway requiring dilutive equity raises or high-cost financing
  • Heightened volatility from convertible debt issuances and associated hedging activity
  • Competitive threats from larger pharma or alternative therapeutic approaches
  • Adverse market sentiment toward small-cap biotech or healthcare risk-off environments limiting capital access
  • Operational execution risks, including enrollment delays, manufacturing or CRO issues

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for IBRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.